STOCK TITAN

NextPlat completes $1.49M Florida pharmacy acquisition

The acquired pharmacy recorded approximately $5.6 million in 2025 sales and is expected to contribute to PharmcoRx during the fourth quarter.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

NextPlat Corp (NXPL) completed its acquisition of an independent pharmacy in a rural community near Pensacola, Florida, and its inventory for total cash consideration of $1,485,439. For the year ended December 31, 2025, the pharmacy generated approximately $5.6 million in sales.

The pharmacy was profitable, maintained positive working capital and operated with a debt-free balance sheet. NextPlat expects it to contribute to continued growth and profitability in the PharmcoRx healthcare segment throughout the fourth quarter. PharmcoRx currently operates five pharmacies serving patients in northern, central and southern Florida.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.The acquired pharmacy generated approximately $5.6 million in 2025 sales; a contribution to PharmcoRx throughout the fourth quarter is expected.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash consideration $1,485,439 Acquisition of the pharmacy and its inventory
Sales Approximately $5.6 million Pharmacy, year ended December 31, 2025
PharmcoRx pharmacies Five pharmacies PharmcoRx currently operates in Florida
working capital financial
"maintained positive working capital"
Working capital is the money a business has available to cover its daily expenses, like paying bills and buying supplies. It’s like the cash in your wallet that helps you handle everyday costs; having enough ensures the business can operate smoothly without running into money shortages.
340B regulatory
"higher-margin contracted services for 340B"
340B is a U.S. federal program that lets qualifying hospitals and clinics buy outpatient prescription drugs at steep, government-negotiated discounts so they can stretch limited budgets and serve low-income or uninsured patients. For investors, 340B affects how much drugmakers earn on certain sales and how safety-net providers generate margin—think of it like a factory discount card that changes both the seller’s revenue and the buyer’s ability to reinvest savings in operations.
claims management technical
"medication fulfillment, claims management and compliance reporting"
Claims management is the process of handling and resolving requests for compensation or benefits, such as insurance claims or legal compensation. It involves reviewing, processing, and settling these claims efficiently to ensure that rightful payments are made and disputes are minimized. Effective claims management helps organizations and individuals recover losses smoothly, which can influence financial stability and decision-making.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did NXPL pay for the Pensacola-area pharmacy?

NextPlat paid $1,485,439 in total cash consideration for the independent pharmacy and its inventory. The pharmacy is in a rural community near Pensacola in northwest Florida.

How much sales did the acquired NXPL pharmacy generate?

The pharmacy generated approximately $5.6 million in sales for the year ended December 31, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0001058307 0001058307 2026-10-06 2026-10-06
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 6, 2026
 
NEXTPLAT CORP
(Exact Name of Registrant as Specified in its Charter)
 
Nevada
 
001-40447
 
65-0783722
(State or Other Jurisdiction
of Incorporation or Organization)
 
(Commission
File No.)
 
(I.R.S. Employer
Identification No.)
 
400 Ansin Blvd, Suite A
Hallandale Beach, FL 33009
(Address of principal executive offices and zip code)
 
(305) 560-5381
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed from last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol (s)
 
Name of each exchange on which registered
Common Stock, par value $0.0001
 
NXPL
 
The Nasdaq Stock Market LLC
 


 
 

 
Item 8.01 Other Events.
 
On October 6, 2026, NextPlat Corp (the “Company”) issued a press release announcing the completion of its previously announced strategic acquisition of an independent pharmacy in the Pensacola area of northwest Florida. NextPlat acquired the pharmacy and its inventory for total cash consideration of $1,485,439. For the year ended December 31, 2025, the pharmacy generated approximately $5.6 million in sales.
 
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
 
Item 9.01. Financial Statements and Exhibits.
 
Exhibits.
 
Exhibit No.
 
Description
99.1
 
Press Release
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
SIGNATURE
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
NEXTPLAT CORP.
     
 
By:
/s/ David Phipps
 
Name:
David Phipps
 
Title:
Chief Executive Officer and President
     
Dated: October 6, 2026
   
 
 

Exhibit 99.1

nextplat_new1logo.jpg

NextPlat Completes Pensacola-Area Acquisition of Profitable Pharmacy, Accelerating Continued Healthcare Growth and Profitability

 

Strategic Acquisition Enhances Pharmacy Diversification into Underserved Market, Supporting the Launch of New High-Value, High Margin Healthcare Services for Regional Providers and Patients

 

Hallandale Beach, FL – October 6, 2026 - NextPlat Corp (NASDAQ: NXPL) (“NextPlat” or the “Company”), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that it has completed the previously announced strategic acquisition of an independent pharmacy (“the Pharmacy”) in a rural community near Pensacola in the panhandle region of northwest Florida.

 

NextPlat acquired the Pharmacy and its inventory for total cash consideration of $1,485,439. For the year ended December 31, 2025, the Pharmacy generated approximately $5.6 million in sales. The Pharmacy was profitable, maintained positive working capital, and operated with a debt-free balance sheet and is expected to contribute to the continued growth and profitability in the Company’s PharmcoRx healthcare segment throughout the fourth quarter.

 

“This acquisition synergistically expands our pharmacy footprint in Florida, adding access to the large Pensacola market and to the greater panhandle region where we have an opportunity to rapidly introduce our full array of high-value service offerings to local patients and providers,” said David Phipps, CEO of NextPlat. “Our teams are quickly working to integrate this pharmacy into our growing PharmcoRx network and see a clear path to enhancing its profitability as we layer in our higher-margin contracted services for 340B, long-term care and senior living providers across a region where those offerings are largely unavailable today. Looking ahead, as we continue to grow organically, we are actively exploring additional opportunities to acquire well-established, profitable community operators that can provide us with diversification and further differentiate our business from traditional mass market retail pharmacies.”

 

NextPlat’s PharmcoRx unit currently operates five pharmacies serving patients in northern, central, and southern Florida providing full-service prescription fulfillment, medication management, high-touch, same day delivery, and integrated patient support and coordination with healthcare providers. Beyond traditional retail pharmacy services, PharmcoRx also provides higher margin contracted services including medication fulfillment, claims management and compliance reporting to 340B providers as well as to long-term care, senior living communities and government agencies.

 

Additional information on this transaction may be found in the Current Reports on Form 8-K that will be filed by NextPlat with the U.S. Securities and Exchange Commission (the “SEC”).

 

For more information about NextPlat, please visit www.NextPlat.com and connect with us on Facebook, LinkedIn and X.

 

About NextPlat Corp

NextPlat is a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide. Through acquisitions, joint ventures, and collaborations, the Company seeks to provide access to high-quality healthcare and pharmacy services supporting patients, providers, institutions, and public-sector organizations and creating online sales channels for the sales of products to domestic and international consumers. Through its subsidiaries, NextPlat provides pharmacy and healthcare data management services and prescription fulfillment services in the United States and operates an e-commerce division offering voice, data, tracking, and IoT products and services worldwide.

 

Forward-Looking Statements

Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company’s business and any of its products, services or solutions. The words “believe,” “forecast,” “project,” “intend,” “expect,” “plan,” “should,” “would,” and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company’s ability to successfully acquire and integrate pharmacies, and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company’s previously reported actual results, performance (financial or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

 

Media and Investor Contact for NextPlat Corp:

Michael Glickman

MWGCO, Inc.

917-397-2272

mike@mwgco.net

 

 

Filing Exhibits & Attachments

5 documents

Keep reading